Mozavaptan

SKU: orb1300900

Description

Mozavaptan (OPC-31260) is a competitive antagonist of vasopressin V1 and V2 receptors, exhibiting respective IC50 values of 1.2 μM and 14 nM. It is a research tool used in vitro and in vivo to study the physiological roles of vasopressin in areas such as renal function, cardiovascular regulation, and hyponatremia.

Research Area

Pharmacology & Drug Discovery

Key Properties

• CAS Number: 137975-06-5
• MW: 427.54
• Purity: 98.98% (May vary between batches)
• Formula: C₂₇H₂₉N₃O₂
• SMILES: CN(C)C1CCCN(C(=O)c2ccc(NC(=O)c3ccccc3C)cc2)c2ccccc12
• Target: Vasopressin Receptor
• Solubility: DMSO:33.33 mg/mL (77.96 mM)

Bioactivity

• Target IC50:
  V1 receptor:1.2 μM|V2 receptor:14 nM
• In Vivo:
  Mozavaptan (OPC-31260) inhibits the antidiuretic action of exogenously administered AVP in water-loaded, alcohol-anaesthetized rats in a dose-dependent manner. OPC-31260 dose-dependently increases urine flow and decreased urine osmolality after oral administration at doses of 1 to 30 mg/kg in normal conscious rats.
  Read more...
• In Vitro:
  Mozavaptan (OPC-31260) is a nonpeptide, orally effective competitive inhibitor of AVP with a V2:V1 receptor selectivity ratio of 25:1 indicating relative V2 receptor selectivity. Mozavaptan (OPC-31260) inhibits AVP binding to V1 and V2 receptors in a competitive manner.
  Read more...

Storage & Handling

• Storage: -20°C
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

AVP, arginine, benzazepine, diuretic, hyponatremia, Inhibitor, Mozavaptan, OPC 31260, OPC31260, OPC-31260, OPC31260l, inhibit, Nonpeptide, SIADH, VasopressinReceptor, vasopressin-V2, Vasopressin receptor 2, Vasopressin Receptor, Vasopressin receptor 1

Compound Identifiers

PubChem CID

119369